| abstract |
The present disclosure provides a compound ephrinA1 in monomeric form, and methods of use of ephrinA1. Included are methods of detecting a cancer tumor expressing the oncogenic receptor EphA2 in a subject, a method of treating a cancer expressing the oncogenic receptor EphA2 in a subject, and a method of treating a cancer in a subject by administering a first compound that specifically binds to Eph receptors, while concurrently administering a second compound that specifically binds to IL13 receptors. |